Regeneron Partnership Lifts Healthcare Sector

Regeneron Pharmaceuticals ($REGN) extended its cancer therapy partnership with CytomX Therapeutics to a $4 billion deal, bringing together CytomX's biologic masking technology with Regeneron's expertise in bispecific antibodies. The expanded collaboration drove $REGN shares up 2.9% as the company also reported positive clinical trial data for one of its treatments. The European Medicines Agency accepted Regeneron's Otarmeni gene therapy for OTOF-related hearing loss for accelerated assessment, reinforcing the company's push into genetic medicines. Eli Lilly ($LLY) announced separate licensing and research agreements with South Korea-based Hanmi Pharm and China-based Haisco Pharmaceutical Group, expanding its access to new drug candidates and discovery programs.

Eli Lilly ($LLY) reported Phase 3 LIBRETTO-432 data showing Retevmo (selpercatinib) cut the risk of recurrence or death in early-stage RET fusion-positive non-small cell lung cancer. The results position Retevmo as a potential new adjuvant standard of care for this genetically defined group of lung cancer patients. Separately, Lilly released encouraging first-in-human data for VERVE-102, a gene-editing therapy targeting cardiovascular disease. Moderna ($MRNA) snapped a four-day losing streak, jumping 7.5% to close at $49.06 per share as investors positioned portfolios ahead of its participation in a conference next week.

Intuitive Surgical ($ISRG) reached $407.29 at the closing of the latest trading day, reflecting a 1.24% gain despite broader market weakness. Analysts remain moderately optimistic about the surgical robotics sector's prospects as companies continue to advance in minimally invasive surgery technologies. Abbott Laboratories ($ABT) expanded its collaboration with MiniMed on dual glucose ketone sensors and received fresh support from the American Cancer Society for its Cologuard colorectal cancer screening tests, though the stock has declined approximately 22% over the past 90 days.

Industry analysts highlighted major managed care players including UnitedHealth ($UNH), The Cigna Group, Humana, Centene, and Molina Healthcare in sector outlook coverage. The health insurance and managed care segment continues to attract attention as companies navigate evolving reimbursement landscapes and Medicare policy changes. Investors are monitoring the sector for potential regulatory developments and enrollment trends heading into the second half of 2026.

Moderna ($MRNA) is set to participate in a conference next week, with investors anticipating key updates on its pipeline programs. Adaptive Biotechnologies management emphasized expanding its minimal residual disease testing business while pursuing targeted partnerships for its Immune Medicine platform at a conference presentation. HSBC downgraded Thermo Fisher Scientific ($TMO), while analysts noted that QuidelOrtho's respiratory exposure remains a key near-term risk as a milder respiratory season can pressure revenue, margins and cash flow despite stable testing market share.